Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Kudo, M; Lim, HY; Cheng, AL; Chao, Y; Yau, T; Ogasawara, S; Kurosaki, M; Morimoto, N; Ohkawa, K; Yamashita, T; Lee, KH; Chen, ER; Siegel, AB; Ryoo, BY

Kudo, M (corresponding author), Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan.

LIVER CANCER, 2021; 10 (3): 275

Abstract

Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with adv......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索